Crinetics Pharmaceuticals
Develops oral GPCR medicines for endocrine diseases and endocrine-related tumors.
$84.97
After-hours close+0.11 (+0.13%)
At close$84.86(+0.01%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 121.04%Insiders 1.22%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 105.97M · Float 99.41M · 93.8% free float
Institutions13F, as of Jun 30, 2026
272 holders · 128.27M shares · 59 new positions · 158 increased · 70 reduced · 34 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 15.84M | 14.95% | +80.4K | Aug 13, 2026 |
| BlackRock, Inc. | 9.76M | 9.21% | +1.28M | Aug 7, 2026 |
| Farallon Capital Management LLC | 8.99M | 8.48% | +651.0K | Aug 14, 2026 |
| Wellington Management Group LLP | 7.13M | 6.73% | −1.03M | Aug 14, 2026 |
| Driehaus Capital Management LLC | 6.46M | 6.10% | +67.6K | Aug 14, 2026 |
| Price T Rowe Associates Inc /MD/ | 6.21M | 5.86% | +857.2K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 4.83M | 4.56% | +194.1K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 4.75M | 4.48% | +71.3K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 13.96M | 13G | May 12, 2025 ↗ |
| Wellington Management Group LLP | 7.80% | 8.16M | 13G | May 15, 2026 ↗ |
| Driehaus Capital Management LLC | 6.11% | 6.40M | 13G | May 15, 2026 ↗ |
| Wellington Investment Advisors Holdings LLPincl. Wellington Management Group LLP, Wellington Group Holdings LLP +1 more | 5.57% | 4.46M | 13G | Nov 8, 2024 ↗ |
| Vanguard Capital Management | 5.19% | 5.44M | 13G | Apr 29, 2026 ↗ |
| T. Rowe Price Associates, Inc. | 5.10% | 5.36M | 13G | May 15, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Richard Scott Struthers | director, officer: President & CEO | 504.7K | 0.48% | Aug 11, 2026 |
| Stephen F. Betz | officer: Chief Scientific Officer | 137.1K | 0.13% | Mar 18, 2026 |
| Wendell Wierenga | director | 122.1K | 0.12% | Jun 22, 2026 |
| Wendall Wierenga | director | 116.1K | 0.11% | Jun 13, 2025 |
| Jeff E. Knight | officer: Chief Dev. & Operating Officer | 105.3K | 0.10% | Apr 10, 2026 |
| Tobin Schilke | officer: Chief Financial & Infra. Ofcr. | 79.4K | 0.07% | Aug 24, 2026 |
| Dana Pizzuti | officer: Chief Med and Dev Officer | 66.8K | 0.06% | Dec 3, 2025 |
| Isabel Kalofonos | officer: Chief Commercial Officer | 34.8K | 0.03% | Feb 25, 2026 |
| Matthew K. Fust | director | 28.8K | 0.03% | Jun 22, 2026 |
| Camille L. Bedrosian | director | 22.2K | 0.02% | Jun 22, 2026 |
3 ten-percent owners hold 5.71M shares by Form 4, outside the officers-and-directors figure above · 5 people have not refiled in the last 18 months (5.68M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 2, 2026 | Coelho Rogerio Vivaldidirector | Sale | 3,000 | $40.00 | 19,225 |
| Jun 17, 2026 | Stephanie Okeydirector | Sale · 2 lots | 6,900 | $35.67 | 6,400 |
| Apr 8, 2026 | Jeff E. Knightofficer: Chief Dev. & Operating Officer | Sale | 85,163 | $40.10 | 105,289 |
| Mar 16, 2026 | Richard Scott Struthersdirector, officer: President & CEO | Sale · 2 lots | 21,981 | $37.37 | 404,778 |
| Mar 16, 2026 | Stephen F. Betzofficer: Chief Scientific Officer | Sale · 2 lots | 10,612 | $37.37 | 137,101 |
| Mar 16, 2026 | Jeff E. Knightofficer: Chief Operating Officer | Sale · 2 lots | 9,911 | $37.37 | 112,018 |
| Mar 12, 2026 | Coelho Rogerio Vivaldidirector | Sale · 2 lots | 5,000 | $36.15 | 16,300 |
| Mar 3, 2026 | Tobin Schilkeofficer: Chief Financial Officer | Sale | 6,713 | $39.67 | 78,121 |
| Mar 3, 2026 | Stephanie Okeydirector | Sale | 3,000 | $39.67 | 13,300 |
| Jan 5, 2026 | Isabel Kalofonosofficer: Chief Commercial Officer | Sale | 2,500 | $55.00 | 834 |
CongressHouse and Senate disclosures
Not reported.